艾迪腹腔灌注治疗晚期胃肠道肿瘤的疗效观察

目的：探索中药艾迪腹腔内灌注辅助常规治疗方法治疗晚期胃肠道肿瘤的疗效。方法：回顾性分析了2005年9月—2009年1月间住院进展期胃肠道肿瘤患者156例,分别接受艾迪腹腔内灌注＋腹腔化疗＋静脉化疗（AD＋IPC＋IVC,54例）、单纯静脉化疗（SIVC,50例）和常规腹腔化疗＋静脉化疗（IPC＋IVC,52例）3种治疗方法,治疗2个周期以上,分析其疗效差异。结果：与IPC＋IVC或SIVC相比,AD＋IPC＋IVC组患者缓解率、总体疗效有明显差异（P〈0.05）,且在治疗转移性腹水方面有明显的优势（P〈0.05）,但对肝转移灶缩小方面的疗效优势不能肯定（P〉0.05）。引起全身不良反应小。患者生活质量改善明显,临床受益率高。结论：对于晚期胃肠道肿瘤患者,AD＋IPC＋IVC疗效好,不良反应小。

Clinical Efficacy of Aidi Peritoneal Infusion for Advanced Gastrointestinal Tumors

OBJECTIVE：To investigate the efficacy of Aidi peritoneal infusion added to routine therapy in the treatment of advanced gastrointestinal tumor.METHODS： A retrospective analysis was performed on a total of 156 inpatients with progressive advanced gastrointestinal tumor between Sept.2005 and Jan.2009 who were treated with one of the following 3 therapeutic schemes,namely,Aidi（peritoneal infusion） plus intraperitoneal chemotherapy and intravenous chemotherapy（AD ＋ IPC ＋ IVC,n = 54）,single intravenous chemotherapy（SIVC,n = 50） and routine intraperitoneal chemotherapy plus intravenous chemotherapy（IPC ＋ IVC,n = 52）.After treatment of more than 2 treatment cycles,the differences in curative efficacy among the three groups were analzyed.RESULTS： There were significant differences in remission rate and the overall response rate between AD ＋ IPC ＋ IVC group and the other two groups（IPC ＋ IVC group or SIVC group）（P 0.05）,and the efficacy in metastatic ascites was signficantly better in AD ＋ IPC ＋ IVC group than the latter two groups（P 0.05）,however,the differences in hepatic metastasis focal diminution were nonsignificant（P 0.05）.The systemic side effects were mild and patients＇ quality of life significantly improved,showing high clinical beneficial rate.CONCLUSION： AD ＋ IPC ＋ IVC is effective and safe（with mild side effects） for patients with advanced gastrointestinal tumor.